Sinovac Revenues Down $SVA $XHS

Sinovac Biotech has announced its annual financial results of FY-14.

The results Shows that Sales downs 13%, Gross Profit down 9.1% and Net Income (EPS) of $0.13 went down to Loss at -$0.02.

View the full earnings release here.